Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Ibrutinib Monotherapy and Combinations in CLL

June 30th 2015

Preventing Infusion Reactions With CD20 Antibodies in CLL

June 30th 2015

Role of B-Cell Receptor Signaling Inhibitors in CLL

June 30th 2015

Changing Treatment Landscape in CLL

June 30th 2015

Future Approaches in Breast Cancer

June 17th 2015

TNT Study for Triple-Negative or BRCA1/2 Breast Cancer

June 17th 2015

Neratinib in HER2-Positive Breast Cancer

June 17th 2015

Clinical Trials for HER2-Positive Breast Cancer

June 17th 2015

Overcoming Resistance in Breast Cancer

June 17th 2015

Improving Endocrine Treatment Decisions in ER+ Breast Cancer

June 17th 2015

Fulvestrant in HR-Positive Breast Cancer

June 17th 2015

Palbociclib in Metastatic Breast Cancer

June 17th 2015

Tumor-Infiltrating Lymphocytes in Breast Cancer

June 17th 2015

Multigene Panel Testing in Breast Cancer

June 17th 2015

Introduction: Biomarkers in Breast Cancer

June 17th 2015

Holli Dilks on Molecular Profiling

June 12th 2015

Holli Dilks, PhD, Director, Personalized Medicine Operations Sarah Cannon Research Institute, discusses molecular profiling.

Potential Bevacizumab Biomarker Identified in Ovarian Cancer

June 10th 2015

A retrospective analysis of the phase III GOG-0218 trial has identified a potential biomarker of response for bevacizumab in patients with advanced ovarian cancer.

Rucaparib Response Rate Exceeds 80% in BRCA-mutant Ovarian Cancer

June 9th 2015

Treatment with the PARP inhibitor rucaparib demonstrated robust clinical activity and a tolerable safety profile for women with biomarker-defined relapsed ovarian cancer

Largest-Ever Precision Medicine Oncology Trial Ready for Launch

June 1st 2015

A landmark clinical trial that will channel patients into treatment arms based on molecular abnormalities rather than cancer types aims to test the efficacy of more than 20 drugs simultaneously in an ambitious National Cancer Institute plan to further propel oncology drug discovery into the precision medicine era.

Off-Label Access to Targeted Therapies Offered Through ASCO's First-Ever Clinical Trial

June 1st 2015

Physicians will now have a new option for some patients who have run out of them, but whose tumors have a genomic variation matching a drug target that is FDA-approved for a different cancer.